This also introduces therapeutic potential of dPLT transfusions to promote immunosuppression or to utilize dPLT as delivery vehicles for antigens requiring cover from immune surveillance, such as replacement FVIII in hemophilia A. Furthermore, in platelet transfusions, dPLT or its derivatives, previously nonutilized because of decreased circulating lifespan, may now have therapeutic utility. The gene discussed is F8; the disease is hemophilia A.